BUTRANS 5 5 MCG
BUPRENORPHINE : 5 MCG · DIN 02341174 · PURDUE PHARMA
Health Canada status: MARKETED
What is BUTRANS 5?
BUTRANS 5 5 MCG contains BUPRENORPHINE : 5 MCG. It is listed in the Health Canada Drug Product Database under DIN 02341174, held by PURDUE PHARMA, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 26-May-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BUTRANS 5 used for?
Management of pain in adults severe enough to require daily, continuous, long-term opioid treatment that is opioid-responsive and for which alternative options are inadequate. Not for as-needed use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02341174 |
|---|---|
| Brand name | BUTRANS 5 |
| Generic / active ingredient | BUPRENORPHINE : 5 MCG |
| Manufacturer | PURDUE PHARMA |
| Strength | 5 MCG |
| Dosage form | PATCH |
| Route of administration | TRANSDERMAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AE01 BUPRENORPHINE |
| AHFS class | 28:08.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-May-2010 |
| Original market date | 2010-05-26 00:00:00 |
How is it administered?
Apply one patch every 7 days. Titrate slowly (min 3 days between adjustments). Rotate application sites; do not reuse same site for 3 weeks. Max dose 20 mcg/h. Do not exceed 90 mg morphine equivalents.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store securely to avoid theft or misuse. (Specific temperature range not provided in text snippet, though standard Purdue Pharma standards apply).
How is it supplied?
Available in strengths of 5, 10, 15, and 20 mcg/h. Supplied in sealed transdermal patches.
Contraindications
Hypersensitivity to buprenorphine; ileus; suspected surgical abdomen; acute pain; acute asthma/respiratory depression; severe CNS depression; MAO inhibitors use; pregnancy/breastfeeding; myasthenia gravis; severe hepatic insufficiency.
Warnings and precautions
Risk of addiction, abuse, misuse; life-threatening respiratory depression; fatal overdose if chewed/swallowed; accidental exposure risk; neonatal opioid withdrawal syndrome; interaction with alcohol.
What can be used instead?
Other Canadian products sharing ATC code N02AE01 BUPRENORPHINE. 4 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUTRANS 10 | 10 MCG | PATCH | PURDUE PHARMA | MARKETED | DIN 02341212 |
| BUTRANS 15 | 15 MCG | PATCH | PURDUE PHARMA | MARKETED | DIN 02450771 |
| BUTRANS 20 | 20 MCG | PATCH | PURDUE PHARMA | MARKETED | DIN 02341220 |
| BAR-BUPRENORPHINE | 10 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | DIN 02493616 |
| BAR-BUPRENORPHINE | 15 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | DIN 02493624 |
| BAR-BUPRENORPHINE | 20 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | DIN 02493632 |
| BAR-BUPRENORPHINE | 5 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | DIN 02493608 |
| BELBUCA | 150 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED POST MARKET | DIN 02465248 |
| BELBUCA | 300 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED POST MARKET | DIN 02465256 |
| BELBUCA | 450 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED POST MARKET | DIN 02465264 |
Who else supplies BUPRENORPHINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUPRENORPHINE appears in 392 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.